Mineralys Therapeutics Statistics
Total Valuation
MLYS has a market cap or net worth of $1.03 billion. The enterprise value is $697.17 million.
Important Dates
The last earnings date was Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MLYS has 65.18 million shares outstanding. The number of shares has increased by 22.76% in one year.
| Current Share Class | 65.18M |
| Shares Outstanding | 65.18M |
| Shares Change (YoY) | +22.76% |
| Shares Change (QoQ) | +6.42% |
| Owned by Insiders (%) | 1.88% |
| Owned by Institutions (%) | 69.85% |
| Float | 43.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.99 |
| P/TBV Ratio | 3.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 26.48
| Current Ratio | 26.48 |
| Quick Ratio | 25.63 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -56.31% and return on invested capital (ROIC) is -37.61%.
| Return on Equity (ROE) | -56.31% |
| Return on Assets (ROA) | -35.87% |
| Return on Invested Capital (ROIC) | -37.61% |
| Return on Capital Employed (ROCE) | -58.99% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.70M |
| Employee Count | 51 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +29.84% in the last 52 weeks. The beta is -0.31, so MLYS's price volatility has been lower than the market average.
| Beta (5Y) | -0.31 |
| 52-Week Price Change | +29.84% |
| 50-Day Moving Average | 14.67 |
| 200-Day Moving Average | 12.58 |
| Relative Strength Index (RSI) | 57.19 |
| Average Volume (20 Days) | 898,264 |
Short Selling Information
The latest short interest is 7.21 million, so 11.06% of the outstanding shares have been sold short.
| Short Interest | 7.21M |
| Short Previous Month | 6.43M |
| Short % of Shares Out | 11.06% |
| Short % of Float | 16.57% |
| Short Ratio (days to cover) | 6.20 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -201.49M |
| Pretax Income | -90.80M |
| Net Income | -188.51M |
| EBITDA | -201.44M |
| EBIT | -201.49M |
| Earnings Per Share (EPS) | -$3.73 |
Full Income StatementBalance Sheet
The company has $343.03 million in cash and n/a in debt, giving a net cash position of $343.03 million or $5.26 per share.
| Cash & Cash Equivalents | 343.03M |
| Total Debt | n/a |
| Net Cash | 343.03M |
| Net Cash Per Share | $5.26 |
| Equity (Book Value) | 341.56M |
| Book Value Per Share | 5.26 |
| Working Capital | 341.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$192.66 million and capital expenditures -$37,000, giving a free cash flow of -$192.70 million.
| Operating Cash Flow | -192.66M |
| Capital Expenditures | -37,000 |
| Free Cash Flow | -192.70M |
| FCF Per Share | -$2.96 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |